Clinical Study

Comparison of Three Chemotherapy Regimens in Elderly Patients with Diffuse Large B Cell Lymphoma: Experience at a Single National Reference Center in Mexico

Table 5

Comparison of our series with other trials.

ReferencesAge (M)/
IPI (HSP)Treatment variations Patients (%)ORCROSPFS/EFS

Marchesi et al. 2013 (R) [16](78)
73
32.8%TWCI36 (49.3%)91.2%67.6%55.5% at 2 yr47.2% at 2 yr
R-CHOP FD22 (30.1%)
R-CHOP AD 14 (19.1%)
R-CVP CV37 (50.7%)69.7% 42.4%24.3% 21.6%

Italiano et al. 2005 (R) [14] (83)
29
12.5%CHOP AD22 (92%)79%62.5%63% at 2 yr50% at 2 yr

Yoshida et al. 2016 (R) [18] (72)
135
69%CHOP46 (34%)82.6%76.1%82.1% at 2 yr72.5% at 2 yr
THP-COP69 (51%)81.2%63.8%67.6% at 2 yr64.8% at 2 yr
Surgery 3 (2%)
Palliative 17 (13%)

Nabhan et al. 2012 (R) [2] (84)
170
62%None100%72%50%44% at 4 yr31% at 4 yr

Peyrade et al. 2011 (R) [11] (83)
149
40%R-CHOP AD100%73%62% 59% at 2 yr 47% at 2 yr

Carson et al. 2015 (R) [25] (83)
476
11%AT198 (41%)28.1 mo
WA87 (18%)13.1 mo
NT191 (40%)1.9 mo

Kreher et al. 2014 (R) [13] (77)
30
27%R-CHOP AD100%87%60%60% at 3 yr49% at 3 yr

Spina et al. 2012 (P) [26] (75)
100
5%Fit (dose at 100%)83%54% at 5 yr84% at 5 yr
Fragile (75% reduction)80%61% at 5 yr67% at 5 yr

Olivieri et al. 2012 (P) [23] (74)
91
29.7%R-CHOP 2154 (59%)81.5%46% at 5 yr
R-CHOP Doxo liposomal22 (25%)64%31%
R-mini-CHOP15 (16%)60%41%

Coiffier et al. 2010 (P) [12] (70)
202
15%None 100%82%75%58% at 5 yr54% at 5 yr

Delarue et al. 2013 (P) [24] (70)
602
13% R-CHOP-21 (295 pts)49%86%74%67% at 3 yr 62% at 3 yr
22% R-CHOP 14 (304 pts)51%72% 60%

This series 
68R-CHOP 5377.3%66%74% at 3 yr70% at 3 yr
75 R-ChOP4868.7%62.5%60% 54%
77.5R-COP4060%52.5%60% 52%

RTX: rituximab, Doxo: doxorubicin, CTX: cyclophosphamide, VCR: Vincristine, PDN: prednisone, AT: treatment with anthracyclines, WA: without anthracyclines, NT: no treatment, FD: full doses, AD: attenuated, CV: conservative, RI: reduced intensity, HSP: high score patients, and TWCI: treatment with curative intention, (R) retrospective and (P) prospective.